Abstract:Objective: To investigate the relationship between 21-gene recurrence risk score (21-Gene RS) and the prognosis and clinicopathological features of hormone receptor (HR) positive, HER2-negative early breast cancer patients who did not receive neoadjuvant therapy. Methods: A total of 469 patients with HR positive and HER2-negative early breast cancer who received surgical treatment in the First Affiliated Hospital, Zhejiang University School of Medicine from January 2014 to October 2017 were selected. Their clinicopathological data were retrospectively analyzed. Tumor tissue samples were collected from patients, and the expression of 21-gene was detected by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR). The 21-Gene RS was calculated according to the Trial Assigning Individualized Options for Treatment (TAILORx) RS grouping and National Surgical Adjuvant Breast and Bowel Project B-20 (NSABP B-20) RS grouping principles. Patients were divided into low (21-Gene RS<11 or 21-Gene RS<18), intermediate (11≤21-Gene RS<26 or 18≤21-Gene RS<31) and high (21-Gene RS≥26 or 21-Gene RS≥31) risk groups, and the clinicopathological features and prognostic differences of patients in different risk groups were compared. Statistical data were compared by chi-square test. Survival analysis was performed using Kaplan-Meier curve analysis and the differences between groups were compared using Log-rank test. Multivariate analysis was conducted by COX regression analysis. Results: Based on TAILORx RS grouping, the proportions of low-risk, intermediate-risk and high-risk groups among the 469 patients were 18.8% (88/469), 48.2% (226/469) and 33.0% (155/469), respectively. Based on NSABP B-20 RS grouping, the proportion of low-risk, intermediate-risk and high-risk groups were 43.1% (202/469), 37.5% (176/469) and 19.4% (91/469), respectively. The association of 21-Gene RS with histological grading, luminal typing, Ki-67 expression, and chemotherapy and treatment modalities were statistically significant (P<0.05) regardless of TAILORx RS grouping or NSABP B-20 RS grouping. Kaplan-Meier survival curve suggested poor prognosis in high-risk group (P<0.05, Log-rank test). Multivariate COX regression analysis showed that surgical method and 21-Gene RS were risk factors affecting the prognosis of patients. Conclusions: 21-Gene RS is significantly associated with the prognosis of patients with HR-positive, HER2-negative, early-stage breast cancer not receiving neoadjuvant therapy, as well as with their clinicopathological characteristics such as patients' histologic grade, luminal typing, Ki-67 expression, and whether or not they are treated with chemotherapy or other treatment modalities.The 21-Gene RS threshold of 11 and 26 or 18 and 31 can be used to grade the prognosis in Chinese patients with early-stage breast cancer. More researches are needed to guide the selection of postoperative adjuvant therapy for patients with HR-positive and HER2-negative early-stage breast cancer.

Differences of prediction performances by multigene assays in patients with breast cancer with distinct genetic backgrounds.

Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis

Impact Of A 21-Gene Recurrence Score Test On The Choice Of Adjuvant Chemotherapy For Hormone Receptor-Positive Early-Stage Breast Cancer: A Prospective Study

The Population Characteristic Analysis in RecurIndex for Clinical Decision-Making on Adjuvant Therapy for Early Breast Cancer: Results of a Real-World Study.

A Novel Approach for 21-Genes Testing Associated with Prognosis in Chinese Patients with ER-positive/HER2-negative Breast Cancer: A Real-World Study.

[Clinical Utility Study of 21-Gene Assay in 927 Chinese Patients with Early Breast Cancer].

Differences in 21-Gene and PAM50 Recurrence Scores in Younger and Black Women With Breast Cancer

[Application of 21-gene recurrence risk score in patients with breast cancer]

Impact of the 21-Gene Expression Assay on Treatment Decisions and Clinical Outcomes in Breast Cancer with One to Three Positive Lymph Nodes

Distribution, Chemotherapy Use, and Outcome of the 21-Gene Recurrence Score Between Chinese and White breast Cancer in the United States

A Retrospective Study of 21-Gene Recurrence Score Assay Compared with Clinicopathological Markers in Node-Negative, Hormone Receptor-Positive, HER2-negative Breast Cancer.

Withdrawal: “Distribution, chemotherapy use, and outcome of the 21‐gene recurrence score between Chinese and White breast cancer in the United States” Guan‐Qiao Li, Jia Yao, Ping Zhou, Dan‐Xia Chen, Chen‐Lu Lian, Shi‐Ping Yang, San‐Gang Wu

Clinical Analysis of 21-Gene Recurrence Score Test in Hormone Receptor-Positive Early-Stage Breast Cancer

Gene Expression Profiling for Breast Cancer Prognosis in Chinese Populations

Cell-free DNA comparative analysis of genomic landscape of first-line hormone-receptor positive metastatic breast cancer from US and China

Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers

Prognostic Comparison between Oncotype DX® and a 23-Gene Classifier, RecurIndex®, on the Taiwan Breast Cancer Population

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

Prognostic Value of the 21-Gene Recurrence Score in ER-positive, HER2-negative, Node-Positive Breast Cancer Was Similar in Node-Negative Diseases: a Single-Center Study of 800 Patients

Clinical analysis of 21-gene recurrence score assay applied in early-stage breast cancer patients